Your browser doesn't support javascript.
loading
[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
Kong, F C; Yu, M; Zhou, Y L; Wang, S X; Li, F.
Afiliación
  • Kong FC; Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Yu M; Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Zhou YL; Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Wang SX; Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Li F; Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Zhonghua Xue Ye Xue Za Zhi ; 43(1): 66-69, 2022 Jan 14.
Article en Zh | MEDLINE | ID: mdl-35231996
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Inmunoconjugados Límite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Inmunoconjugados Límite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China